Clinical trial results
Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
July 10, 2023 08:30 ET | Nexalin Technology, Inc.
HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that Company’s abstract, titled: “MEG Source Imaging Reveals...
nexalin.jpg
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region
June 01, 2023 08:30 ET | Nexalin Technology, Inc.
HOUSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced it has formalized a joint venture arrangement (“JV”) with Wider...
nexalin.jpg
Nexalin Technology Provides 2022 Year-End Business Update
March 27, 2023 07:00 ET | Nexalin Technology, Inc.
HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided a business update for the year ended December 31, 2022. Mark...
nexalin.jpg
Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory
January 24, 2023 08:30 ET | Nexalin Technology, Inc.
HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of Michael Nketiah as Senior Vice President of...
nexalin.jpg
Nexalin Technology CEO Provides Letter to Shareholders
January 05, 2023 08:30 ET | Nexalin Technology, Inc.
HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today provided the following business update and letter to shareholders from...
nexalin.jpg
Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
November 14, 2022 14:00 ET | Nexalin Technology, Inc.
The Second Xiangya Hospital of Central South University, China, reports positive patient results, including disappearance of all somatic anxiety symptoms and improved quality of sleep Treatment...
nexalin.jpg
Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering
September 20, 2022 13:12 ET | Nexalin Technology, Inc.
HOUSTON, TEXAS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the closing of its previously announced initial public offering of 2,315,000...
nexalin.jpg
Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering
September 15, 2022 20:54 ET | Nexalin Technology, Inc.
HOUSTON, TEXAS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the pricing of its initial public offering of 2,315,000 units consisting of...